Safety and Efficacy of Palbociclib (CDK4/6 inhibitor) and Radiotherapy in Metastatic Breast Cancer Patients: Initial Results of a Novel Combination

被引：0
|
作者：
Chowdhary, M. [1 ]
Sen, N. [1 ]
Chowdhary, A. [2 ]
Usha, L. [1 ]
Cobleigh, M. [1 ]
Wang, D. [1 ]
Patel, K. [3 ]
Barry, P. N., Jr. [1 ]
Rao, R. [1 ]
机构：
[1] Rush Univ, Med Ctr, Chicago, IL 60612 USA
[2] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA
[3] Yale Sch Med, New Haven, CT USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2019年 / 105卷 / 01期
关键词：
D O I：
10.1016/j.ijrobp.2019.06.619
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2002
引用
收藏
页码：E2 / E2
页数：1
相关论文
共 50 条
  • [21] Identification of potential novel drivers and biomarkers of CDK4/6 inhibitor resistance in metastatic breast cancer
    Ott, Leonie F.
    Alawi, Malik
    Stoupiec, Malgorzata
    Laakmann, Elena
    Kriegs, Malte
    Muller, Volkmar
    Pantel, Klaus
    Riethdorf, Sabine
    CANCER RESEARCH, 2024, 84 (06)
  • [22] Discovery of a novel covalent CDK4/6 inhibitor based on palbociclib scaffold
    Shan, Huifang
    Ma, Xinyu
    Yan, Guoyi
    Luo, Meng
    Zhong, Xinxin
    Lan, Suke
    Yang, Jie
    Liu, Yuanyuan
    Pu, Chunlan
    Tong, Yu
    Li, Rui
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, 219
  • [23] Anti-cancer stem cell activity of the CDK4/6 inhibitor palbociclib in breast cancer cells
    Kishino, E.
    Ogata, R.
    Saitoh, W.
    Koike, Y.
    Ohta, Y.
    Kanomata, N.
    Moriya, T.
    Kurebayashi, J.
    BREAST, 2019, 44 : S28 - S28
  • [24] Clinicopathological Features Related to the Efficacy of CDK4/6 Inhibitor-Based Treatments in Metastatic Breast Cancer
    Shikanai, Ayana
    Horimoto, Yoshiya
    Ishizuka, Yumiko
    Uomori, Toshitaka
    Nakai, Katsuya
    Arakawa, Atsushi
    Saito, Mitsue
    BREAST CANCER-BASIC AND CLINICAL RESEARCH, 2022, 16
  • [25] Treatment with CDK4/6 Inhibitor in a Patient with Metastatic Breast Cancer Causing Myelophthisis
    Dahake, Nikita
    Senchak, Jordan
    Nasibli, Jalil
    Incorvati, Jason
    CANCER RESEARCH, 2024, 84 (09)
  • [26] Safety of CDK4/6 inhibitors and concomitant radiation therapy in patients affected by metastatic breast cancer
    Visani, L.
    Becherini, C.
    Scoccimarro, E.
    Valzano, M.
    Saieva, C.
    Ratosa, I.
    Ribnikar, D.
    Orazem, M.
    Marinko, T.
    Desideri, I.
    Scotti, V.
    Morandi, A.
    Lambertini, M.
    Meattini, I.
    Livi, L.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S643 - S643
  • [27] Safety of CDK4/6 inhibitors and concomitant radiation therapy in patients affected by metastatic breast cancer
    Visani, Luca
    Livi, Lorenzo
    Ratosa, Ivica
    Orazem, Miha
    Ribnikar, Domen
    Saieva, Calogero
    Becherini, Carlotta
    Salvestrini, Viola
    Scoccimarro, Erika
    Valzano, Marianna
    Cerbai, Cecilia
    Desideri, Isacco
    Bernini, Marco
    Orzalesi, Lorenzo
    Nori, Jacopo
    Bianchi, Simonetta
    Morandi, Andrea
    Meattini, Icro
    RADIOTHERAPY AND ONCOLOGY, 2022, 177 : 40 - 45
  • [28] CDK4/6 inhibitors in the treatment of metastatic breast cancer: Focus on toxicity and safety
    Wekking, Demi
    Lambertini, Matteo
    Dessi, Mariele
    Denaro, Nerina
    Bardanzellu, Fabio
    Garrone, Ornella
    Scartozzi, Mario
    Solinas, Cinzia
    SEMINARS IN ONCOLOGY, 2023, 50 (06) : 131 - 139
  • [29] Novel therapeutic strategy for melanoma based on albendazole and the CDK4/6 inhibitor palbociclib
    Lin Zhu
    Qin Yang
    Rong Hu
    Yanan Li
    Yuanliang Peng
    Hong Liu
    Mao Ye
    Bin Zhang
    Peihe Zhang
    Feng Liu-Smith
    Hui Li
    Jing Liu
    Scientific Reports, 12
  • [30] Novel therapeutic strategy for melanoma based on albendazole and the CDK4/6 inhibitor palbociclib
    Zhu, Lin
    Yang, Qin
    Hu, Rong
    Li, Yanan
    Peng, Yuanliang
    Liu, Hong
    Ye, Mao
    Zhang, Bin
    Zhang, Peihe
    Liu-Smith, Feng
    Li, Hui
    Liu, Jing
    SCIENTIFIC REPORTS, 2022, 12 (01)
12345